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Summary  Smokeless  tobacco  (snuff)  is  a  ﬁnely  ground  or  shredded  tobacco  that  is  sniffed
through the  nose  or  placed  between  the  cheek  and  gum.  Chewing  tobacco  is  used  by  putting
a wad  of  tobacco  inside  the  cheek.  Smokeless  tobacco  is  widely  used  by  young  athletes  to
enhance performance  because  nicotine  improves  some  aspects  of  physiology.  However,  smoke-
less tobacco  has  harmful  health  effects,  including  cardiovascular  disorders,  linked  to  nicotine
physiological  effects,  mainly  through  catecholamine  release.  Nicotine  decreases  heart  rate
variability  and  the  ventricular  ﬁbrillation  threshold,  and  promotes  the  occurrence  of  various
arrhythmias;  it  also  impairs  endothelial-dependent  vasodilation  and  could  therefore  promote
premature  atherogenesis.  At  rest,  heart  rate,  blood  pressure,  inotropism,  cardiac  output  and
myocardial  oxygen  consumption  are  increased  by  nicotine,  leading  to  an  imbalance  between
myocardial  oxygen  demand  and  supply.  The  same  occurs  at  submaximal  levels  of  exercise.
These increases  are  accompanied  by  a  rise  in  systemic  resistances.  At  maximal  exercise,  heart
rate, cardiac  output  and  maximal  oxygen  uptake  (V˙O2  max)  are  unaffected  by  nicotine.  Because
endothelial  dysfunction  is  promoted  by  nicotine,  paradoxical  coronary  vasoconstriction  may
occur during  exercise  and  recovery.  Nicotine  induces  a  decrease  in  muscular  strength  and
impairs anaerobic  performance.  However,  nicotine  is  used  in  sports  as  it  diminishes  anxiety,
enhances  concentration  and  agility,  improves  aerobic  performance  and  favours  weight  control.
Abbreviations: SLT, smokeless tobacco; VO2max, maximal oxygen uptake; WADA, World Anti-Doping Agency.
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Importantly,  smokeless  tobacco,  similar  to  cigarette  smoking,  leads  to  nicotine  dependence
through dopaminergic  pathways.  Smokeless  tobacco  has  harmful  cardiovascular  effects  and  is
addictive: it  fulﬁls  all  the  criteria  for  inclusion  in  the  World  Anti-Doping  Agency  prohibited  list
as a  doping  product.  Smokeless  tobacco  use  in  sporting  activities  must  be  discouraged.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  tabac  non  fumé  (TNF)  est  un  tabac  ﬁnement  moulu  ou  broyé  qui  peut  être  placé
soit dans  le  nez  (dry  snuff,  tabac  à  priser)  ou  entre  la  joue  et  la  gencive  (moist  snuff,  snus,
tabac à  chiquer).  Le  TNF  est  utilisé  couramment  par  les  jeunes  athlètes  qui  pensent  ainsi
pouvoir augmenter  leur  performance  sportive,  la  nicotine  améliorant  certains  paramètres  phys-
iologiques. Cependant,  le  TNF  a  des  effets  nocifs  sur  la  santé,  entraînant  notamment  des
troubles cardiovasculaires,  liés  aux  effets  physiologiques  de  la  nicotine,  principalement  via
une libération  de  catécholamines.  La  nicotine  diminue  la  variabilité  de  la  fréquence  cardiaque
(FC), le  seuil  de  ﬁbrillation  ventriculaire  et  favorise  la  survenue  d’arythmies.  Elle  altère  la
vasodilatation  dépendante  de  l’endothélium  et  pourrait  donc  favoriser  le  développement  pré-
maturé d’athérome.  Au  repos,  la  FC  et  la  pression  artérielle  (PA),  ainsi  que  l’inotropisme,  le
débit cardiaque  et  la  consommation  myocardique  d’oxygène  sont  augmentées  par  la  nicotine,
conduisant  à  un  déséquilibre  entre  la  demande  et  l’apport  en  oxygène  au  niveau  myocardique.
Ceci est  également  constaté  à  des  niveaux  d’effort  sous-maximal.  Ces  modiﬁcations  sont  accom-
pagnées d’une  élévation  des  résistances  périphériques.  À  l’exercice  maximal  cependant,  la  FC,
le débit  cardiaque  et  à  le V˙O2  max sont  inchangés  par  la  nicotine.  Puisqu’un  dysfonctionnement
endothélial  est  favorisé  par  la  nicotine,  une  vasoconstriction  coronaire  paradoxale  peut  sur-
venir aussi  bien  pendant  l’exercice  que  pendant  la  phase  de  récupération.  La  nicotine  diminue
la force  musculaire  et  altère  la  capacité  d’exercice  anaérobie.  Cependant,  elle  est  consom-
mée dans  certains  sports  car  elle  diminue  l’anxiété,  renforce  la  concentration,  améliore  la
performance  aérobie  et  favorise  le  contrôle  de  la  prise  de  poids.  Il  est  important  de  savoir  que
le TNF,  à  l’instar  du  tabac  fumé,  entraîne  une  dépendance  à  la  nicotine,  relevant  de  mécan-
ismes dopaminergiques.  L’usage  du  TNF  possède  des  effets  cardiovasculaires  nocifs,  et  induit
une dépendance  à  la  nicotine  :  le  TNF  remplit  donc  les  critères  pour  être  incorporé  à  la  liste
des produits  dopants  de  l’Agence  mondiale  antidopage.  L’utilisation  du  TNF  doit  donc  être
déconseillée  dans  le  cadre  de  la  pratique  sportive.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Fackground
ver  the  past  two  decades,  the  use  of  alternative  kinds
f  tobacco  consumption,  such  as  smokeless  tobacco  (SLT)
n  the  form  of  ‘snuff’,  chewing  tobacco,  snus  or  ‘tabac  à
hiquer’  in  France,  has  increased  in  young  athletes.  SLT
s  chewed  or  sniffed  but  not  smoked.  Although  the  nega-
ive  health  effects  of  cigarette  smoking  have  been  largely
ocumented,  those  of  SLT  remain  controversial.  SLT  has
een  shown  to  be  associated  with  an  increased  risk  of  oral
r  oropharyngeal  cancer  and  cardiovascular  diseases  [1,2],
eading  to  the  strong  discouragement  of  its  use  [3].  Although
o  ﬁrm  association  was  found  between  SLT  use  and  the  risk
f  myocardial  infarction  in  a  pooled  analysis  of  prospec-
ive  observational  studies  [4],  quitting  snus,  a  humid  form
f  powdered  tobacco  placed  under  the  lip,  after  myocar-
ial  infarction  has  recently  been  associated  with  a  better
rognosis  [5].
Current  guidelines  recommend  that  tobacco,  including
LT,  must  be  avoided  for  2  hours  before  and  after  a sports
ession  or  practice  [6].  However,  given  that  SLT  is  mostly
sed  by  athletes  and  that  intense  physical  exercise  can
nduce  acute  cardiovascular  events  [7],  it  is  important  to
w
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[etermine  whether  the  cardiovascular  effects  of  nicotine
an  increase  the  risk  of  cardiovascular  outcomes,  especially
uring  sports  activities.  Nicotine  is  currently  under  evalua-
ion  as  a  doping  product  by  the  World  Anti-Doping  Agency
8].  As  nicotine  contributes  substantially  to  the  cardiovas-
ular  effects  of  tobacco  [9], the  debate  could  be  extended
o  e-cigarettes.
We  aim  to  review  current  knowledge  regarding  SLT  as  a
ardiovascular  risk  factor,  considering  patterns  of  consump-
ion  of  SLT  around  the  world,  the  pharmacological  properties
f  SLT,  the  context  of  SLT  use  by  athletes  and  SLT  safety  data.
inally,  we  review  the  main  ﬁndings  on  the  cardiovascular
mpact  of  SLT  and  discuss  whether  SLT  can  be  classiﬁed  as  a
oping  agent.
orldwide consumption patterns
ew  data  are  available  on  the  real  use  of  SLT  across  the
orld.  In  the  USA,  SLT  use  is  frequent  among  athletes,
specially  baseball  players  [1,10].  In  Scandinavia,  SLT  use
s  common  both  in  the  community  and  among  athletes
1,11],  and  often  starts  early  in  life;  more  than  15%  of
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ﬁSmokeless  tobacco,  sport  and  the  heart  
boys  aged  between  14  and  15  years  were  found  to  have
used  snuff  [12].  SLT  use  is  even  more  frequent  among
individuals  participating  in  sports  club  activities,  espe-
cially  team  sports,  such  as  ice  hockey  [11].  In  Sweden,
the  only  European  Union  country  where  the  sale  of  snuff
is  allowed,  SLT  represents  almost  50%  of  total  tobacco
consumption  [13].  Cigarette  smoking  in  Sweden  is  much
lower  than  that  in  neighbouring  countries,  and  tobacco-
related  mortality  is  about  50%  lower  than  in  other  European
countries  [13].  However,  the  interplay  between  SLT  and
cigarette  smoking  is  complex.  Switching  patterns  exist
in  both  directions  and  both  types  of  consumption  can
be  concomitant  [1].  The  consumption  of  snus  and  chew-
ing  tobacco  is  much  lower  among  young  Swiss  men
[14].
In  France,  epidemiological  data  are  controversial.  Among
920  students  from  the  Alpine  region,  11.2%  had  tried  chew-
ing  tobacco  [15].  However,  SLT  use  has  been  reported  in
French  ice  hockey  players  and  skiers  [16].  In  France,  as  in
other  European  countries  (except  Sweden  and  Norway),  the
sale  of  snuff  is  prohibited.  SLT  can  be  purchased  via  the
Internet  or  brought  in  by  relatives  or  friends  travelling  from
countries  such  as  the  USA,  Norway  or  Sweden,  where  the
sale  of  SLT  is  allowed.  In  France,  the  snuff-provider  role  of
team  partners  and  coaches  travelling  from  such  countries
must  not  be  underestimated.  Moreover,  chewing  tobacco  is
sold  legally  in  France,  which  explains  why  some  athletes  use
it.
Analysis  of  urine  from  2185  athletes  worldwide  suggests
that  nicotine  is  used  for  reasons  other  than  recreational  pur-
poses  [17],  especially  in  certain  sports,  such  as  American
football,  ice  hockey  and  wrestling.
Pharmacology
SLT  includes  chewing  tobacco,  spit  tobacco,  dry  snuff,  which
is  sniffed  into  the  nose,  and  moist  snuff  (snus),  which  is
placed  in  the  mouth  between  cheek  and  gum.  Quantita-
tively,  nicotine  is  the  most  abundant  alkaloid  component
of  tobacco;  it  is  thus  assumed  that  nicotine  is  one  of  the
major  causes  of  the  pharmacological  effects  of  tobacco  [9].
The  concentration  of  nicotine  in  snuff  is  approximately  twice
that  in  chewing  tobacco.
Pharmacokinetics
After  ingestion  of  SLT,  nicotine  absorption  by  the  oral  mucosa
is  rapid  and  massive  [18,19],  and  is  increased  in  some  prepa-
rations  by  the  adjunction  of  very  small  particles  of  glass.
Plasma  nicotine  concentration  shows  a  peak  that  is  nearly
as  high  as  that  obtained  by  cigarette  smoking,  with  a  time
to  peak  after  snuff  intake  of  about  30  minutes.  This  peak
is  then  followed  by  a  plateau  phase,  which  lasts  about
2  hours,  and  is  thus  much  longer  than  with  cigarette  smok-
ing.  Interestingly,  nicotine  absorption  lasts  for  1  hour  after
the  SLT  has  been  removed  from  the  mouth.  For  these  rea-
sons,  exposure  to  nicotine  after  snuff  intake  is  nearly  twice
that  after  cigarette  smoking.  The  half-life  of  nicotine  is
about  2  hours.  Nicotine  is  mostly  metabolized  by  the  liver;
the  main  metabolite,  cotinine,  is  inactive  and  has  a  much
longer  half-life  (about  16  hours)  than  nicotine.  Cotinine  is
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ound  in  the  blood  and  urine;  this  issue  is  important  for
iological  assessments  of  consumption.
harmacodynamics
ost  of  the  effects  of  SLT  are  attributable  to  nicotine
9]. This  alkaloid  binds  to  nicotinic  receptors,  which  are
ocated  in  the  brain,  the  autonomic  ganglia,  the  adrenals
nd  neuromuscular  junctions.  The  stimulation  of  these
eceptors  by  nicotine  induces  the  release  of  neurome-
iators  (e.g.  norepinephrine,  epinephrine,  acetylcholine,
opamine,  serotonin,  vasopressin,  nitric  oxide,  etc.).  Most
ardiovascular  effects  are  due  to  the  secretion  of  cate-
holamines:  either  norepinephrine  by  sympathetic  nerve
erminals  or  epinephrine  by  the  adrenomedulla  [9].  Direct
ffects  can  also  occur,  independently  of  nicotinic  cholin-
rgic  receptors  and  catecholamine  release  [20];  nicotine
an  block  ionic  channels  [21]  at  nicotine  concentrations
hat  are  achieved  after  SLT  use  [20].  Nicotine  may  increase
arotid  and  aortic  chemoreceptor  sensitivity  [22].  Some
uthors  have  suggested  that  the  sympathetic  response  may
e  attributable  to  a  reaction  induced  by  parasympathetic
ffects  [22].  These  mechanisms  could  explain  the  polyphasic
nd  dose-dependent  response  to  nicotine.  The  cognitive  and
ddictive  effects  are  mainly  caused  by  dopaminergic  stimu-
ation,  especially  in  the  nucleus  accumbens  and  prefrontal
rea  [23].
The  tolerance  phenomenon  is  a  key  issue  for  the  effects
f  nicotine,  as  it  occurs  very  early  after  nicotine  expo-
ure.  If  the  blood  nicotine  peak  is  progressive,  as  is  the
ase  with  nicotine  gum  or  patches,  tolerance  effects  induce
ess  intense  cardiovascular  effects  than  other  means  of
dministration,  such  as  intravenous  infusion,  snuff  dipping
r  cigarette  smoking.
se in athletes
thletes  have  different  motivations  for  SLT  consumption,
ncluding  enhanced  concentration,  help  with  relaxation  or
or  ritual  reasons  [10]; sometimes  they  use  SLT  for  weight
ontrol  [24].  Athletes  also  think  that  SLT  can  enhance  their
erformance  [16,24]; however,  this  belief  was  not  reported
n  baseball  players  who  answered  anonymous  questionnaires
10].
It  has  been  suggested  that  SLT  provides  the  ‘beneﬁcial’
ffects  of  nicotine  without  the  negative  effects  of  smoke,
specially  on  the  respiratory  tract.  During  the  2009  Ice
ockey  World  Championship,  nicotine  and  its  metabolites
ere  detectable  in  nearly  50%  of  72  urine  samples,  suggest-
ng  active  tobacco  consumption.  Moreover,  two  athletes  had
uite  elevated  concentrations,  which  is  highly  suggestive  of
LT  use  for  doping  purposes  [25].
Baseball  players  use  SLT  more  often  during  the  baseball
eason  than  during  the  off-season  [10].  However,  long-term
LT  use  failed  to  improve  physical  performance  in  middle-
ged  men  [26]. Moreover,  in  this  cohort  of  144  Swedish
remen,  maximal  oxygen  uptake  (V˙O2 max)  and  maximal
orkload  during  a  bicycle  stress  test  were  similar  in  SLT
sers  and  nonusers  of  tobacco,  but  higher  than  in  cigarette
mokers.  Data  from  a  meta-analysis  on  the  effects  of  nico-
ine  found  that  nicotine  signiﬁcantly  improved  ﬁne  motor
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bilities,  alerting  attention-accuracy  and  response  time,
nd  orienting  attention-response  time  [27].  However,  reac-
ion  and  movement  times  were  similar  in  SLT  users  and
onusers  after  nicotine  absorption  [28,29].  Moreover,  antic-
pation  time  was  also  similar  in  both  groups.  In  contrast,
he  abilities  to  face  cognitively  challenging  tasks  and  to
anage  stressful  situations  were  better  in  SLT  users,  and
he  anxiety-scale  response  during  tests  was  lower.  Interest-
ngly,  with  the  intake  of  increasing  amounts  of  SLT  [29],  no
ose-response  effect  was  found  regarding  performance  and
elf-reported  anxiety.  Although  some  beneﬁcial  effects  are
bserved,  caution  must  be  taken,  given  that  these  tests  have
ajor  limitations:  as  tests  are  often  performed  in  current
sers  during  a  withdrawal  period,  it  is  sometimes  difﬁcult
o  separate  what  is  due  to  the  beneﬁcial  effects  of  the  SLT
rom  what  is  due  to  correction  as  a  result  of  withdrawal  [27].
The  scoring  performances  of  baseball  players  were  simi-
ar  for  users  and  nonusers  [30].  SLT  use  induced  a  decrease
n  the  muscular  strength  of  athletes  [31].  In  contrast,  partic-
pation  in  brief  high-intensity  exercise  (such  as  the  Wingate
naerobic  test)  was  unchanged  after  SLT  [24]. SLT  can  impair
naerobic  performance  [32].  In  some  studies,  maximal  effort
as  not  improved  [32,33]  and  lactate  accumulation  occurred
arlier  [32];  this  could  be  deleterious  for  exercise,  with  an
arlier  anaerobic  threshold  [32]. V˙O2 max was  found  to  be
imilar  with  and  without  SLT  [32].
Interestingly,  transdermal  nicotine  administration  was
ound  to  increase  performance  during  aerobic  exercise,
robably  through  delayed  central  perception  of  fatigue.
lso,  nicotine  increases  pain  tolerance;  it  also  reduces
ppetite  and  enhances  lipolysis  [6,34],  thus  promoting
eight  loss.  The  potential  effects  of  nicotine  on  perfor-
ance  are  summarized  in  Table  1.
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Table  1  Factors  of  performance  potentially  affected  by  nicot
Target  Nicotine  effect
Aerobic  endurance Improved  
Weight  control  Improved  
Anxiety  Diminished  
Ability  to  face  complex  situation  Improved  
Fine  motor  abilities  Improved  
Reaction  time  Improved  
Unaffected  
Anticipation  time Unaffected  
Movement  time  Unaffected  
Anaerobic  maximal  performance Unaffected  
V˙O2 max Unaffected  
Thermoregulation  Possibly  impair
Anaerobic  thresholds Impaired  
Strength  Impaired  
SLT: smokeless tobacco; V˙O2 max: maximal oxygen uptake.F.  Chagué  et  al.
ardiovascular effects
he  cardiovascular  effects  of  nicotine  have  been  studied  in
cute  and  chronic  conditions  [9]. Discrepancies  are  found  in
xperimental  data,  and  are  probably  linked  to  the  different
pecies  used  (rat,  swine,  dog,  calf),  the  conditions  (whether
naesthetized  or  not)  and  the  nicotine  doses;  discrepan-
ies  are  also  found  between  animal  and  human  studies.
oreover,  results  may  also  vary  between  usual  SLT  users
nd  nonusers,  because  of  the  tolerance  effect.  However,  in
umans,  as  nicotine  was  most  often  tested  in  usual  SLT  users,
ome  results  could  be  affected  by  suppression  of  withdrawal
ffects  [22].
rrhythmia
icotine  has  been  shown  to  induce  many  proarrhythmic,
ose-dependent  and  polyphasic  effects,  which  are  partly
ediated  through  catecholamine  release.  Nicotine  acts  by
rolonging  action  potentials  and  membrane  depolarization
21], thereby  promoting  arrhythmia.
Nicotine  has  multiple  direct  effects  on  ionic  channels,
ia  blockade  of  many  types  of  potassium  channels  [20,21].
icotine  decreases  heart  rate  variability  by  acting  on  the
utonomic  nervous  system  [22].  The  ventricular  ﬁbrillation
hreshold  was  found  to  be  decreased  [5,6]. In  anaesthetized
ogs,  low  doses  of  nicotine  (equivalent  to  <  1  cigarette)
id  not  induce  signiﬁcant  changes  in  the  electrocardio-
ram,  but  higher  doses  had  signiﬁcant  effects,  ranging
rom  ectopic  premature  beats  to  ventricular  ﬁbrillation
35]. Interestingly,  the  response  to  nicotine  was  tripha-
ic  and  included  immediate  bradycardia,  with  or  without
trioventricular  block  (probably  linked  to  the  Bezold-Jarish
ine.
 Nicotine  administration
SLT  Other  than  SLT
[34]
[34]
[29]
[29]
[27]
[27]
[28,29,31]
[29]
[28]
[24]
[32]
ed  [34]
[32]
[31]
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Table  2  Cardiovascular  effects  of  nicotine  at  rest.
Target  Nicotine  effect  Nicotine  administration
SLT Other  than  SLT
Ventricular  ﬁbrillation  threshold  Lowered  [6]
Heart  rate  variability Impaired  [22]
Arrhythmia  Increased  [35]
Heart  rate Increased  [18,32,41,42]
Blood  pressure Increased  [18,32,41,42]
Stroke  volume Impaired  [32,33]
Increased  [43]
Cardiac  output  Unaffected  [32]
Increased  [43]
Systemic  vascular  resistance Increased  [41]  [43]
Coronary  vasoconstriction  Increased  [3,46]
Coronary  blood  ﬂow Impaired  [45,46]
Myocardial  oxygen  consumption  Increased  [43]
Endothelial  function Impaired  [37]  [38]
Angiogenesis  Increased  [50]
Atherogenesis  Accelerated  [50]
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reﬂex),  followed  by  a  parasympathetic  response  (bradycar-
dia,  atrial  arrhythmia)  and  then  a  sympathetic  response
(sinus  tachycardia,  atrial  and  ventricular  arrhythmia  includ-
ing  ventricular  tachycardia).  The  underlying  mechanisms  are
complex,  through  both  the  direct  effect  of  nicotine  and  the
autonomic  nervous  system.  These  effects  may  be  aggravated
by  free  fatty  acid  release  [3]  or  myocardial  ischaemia.
Endothelial dysfunction
Endothelial  dysfunction  plays  a  major  role  as  an  early  marker
of  cardiovascular  risk,  and  there  is  a  close  relationship
between  endothelial  function  in  human  coronary  and  periph-
eral  circulation  [36].  Endothelial-dependent  vasodilation  is
impaired  by  nicotine  use  [37,38],  through  catecholamine
release  and  oxidative  stress  [39].  In  humans,  most  studies
have  been  conducted  in  chronic  SLT  users  or  cigarette  smok-
ers  [37,38].  SLT  users  have  the  same  endothelial  dysfunction
as  smokers  [37].
During  strenuous  exercise,  oxidative  stress,  the  proco-
agulant  state  and  platelet  activity  are  increased  [7,40].  In
contrast,  although  nicotine  has  no  effect  on  platelet  activa-
tion  [3],  it  aggravates  oxidative  stress  and  the  procoagulant
state  [6,39].  These  effects  can  have  a  dramatic  impact  dur-
ing  effort  and  at  recovery.
Haemodynamic effects
At rest
The  haemodynamic  effects  of  nicotine  have  been  well
documented  (Table  2).  In  dogs  and  humans,  the  use
i
a
b
tf  oral  SLT  increases  resting  heart  rate  and  blood
ressure  [18,32,33,41]  through  sympathetic  stimulation
18,32,33,42], in  both  SLT  users  and  nonusers  [41].
aemodynamic  modiﬁcations  are  related  to  epinephrine
elease  [42].  In  dogs,  inotropism  and  myocardial  oxygen
onsumption  are  markedly  increased  [43], with  no  major
nvolvement  of  the  baroreﬂex.  The  blood  pressure  rise
hat  accompanies  tachycardia  is  rather  related  to  nicotine-
nduced  stimulation  of  the  central  sympathetic  nerve  system
nd  the  local  release  of  catecholamines  from  cardiac  sym-
athetic  nerve  terminals.  After  the  administration  of  a  4 mg
icotine  tablet,  there  was  an  increase  in  muscle  sympa-
hetic  nerve  activity  [44]. Some  authors  further  observed
 biphasic  response,  with  a  short  initial  phase  in  which
he  baroreﬂex  could  be  involved  [43].  Cardiac  output  and
troke  volume  are  elevated  in  dogs  [43],  but  only  mildly
o,  and  are  reduced  in  humans  [33]. In  addition,  an  ani-
al  study  showed  that  nicotine  could  induce  post-ischaemic
yocardial  dysfunction,  probably  via  a  mechanism  involving
ncreased  oxidative  stress  [9].
Nicotine  has  controversial  effects  on  vascular  resistance,
anging  from  a  lack  of  any  effect  [42]  to  vasoconstric-
ion  [43]. Impaired  coronary  blood  ﬂow  is  partly  mediated
hrough  alpha-adrenergic  vasoconstriction  [3]  and  other
echanisms,  as  shown  after  adrenergic  blockade  [45].  Coro-
ary  blood  ﬂow  decreases  with  impaired  coronary  ﬂow
eserve  after  nicotine  absorption  in  dogs  [41,43].  Nicotine
nduces  an  imbalance  between  myocardial  oxygen  demand
nd  supply  [46];  these  authors  suggested  that  coronary
lood  ﬂow  could  be  decreased  via  coronary  vasoconstric-
ion  and  the  elevation  of  intramyocardial  pressure.  Nicotine
80  F.  Chagué  et  al.
Table  3  Haemodynamic  effects  of  nicotine  during  exercise.
Condition  Target  Nicotine  effect  Nicotine  administration
SLT Other  than  SLT
Submaximal  exercise  Heart  rate  Increased  [32]
Blood  pressure Increased  [48]
Stroke  volume Diminished  [32]
Cardiac  output Increased  [32]
Systemic  vascular  resistance  Increased  [49]
Myocardial  oxygen  consumption  Increased  [49]
Myocardial  blood  ﬂow  Increased  [46,49]
Maximal  exercise  Heart  rate  Unaffected  [32]
V˙O2 max Unaffected  [32]
Recovery  Heart  rate  Increased  [33,48]
Blood  pressure  Unaffected  [33,48]
SLT: smokeless tobacco; V˙O : maximal oxygen uptake.
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se  has  been  reported  to  stimulate  muscarinic  receptors,
iving  a  biphasic  response  that  ﬁrst  consists  of  vasoconstric-
ion  followed  by  vasodilation.  Interestingly,  this  effect  was
bserved  with  nicotine  blood  levels  close  to  those  reached
y  SLT  users  [47].
Vasoconstriction  has  been  documented  in  anaesthetized
ogs  under  nicotine  [45].  Nicotine  can  induce  vasoconstric-
ion  of  skin  vasculature  [34];  this  can  be  deleterious  during
rolonged  exercise  by  compromising  thermoregulation.
uring exercise
ata  on  the  effect  of  nicotine  during  exercise  are  shown
n  Table  3;  potential  deleterious  interferences  can  be  seen
n  Fig.  1.  At  maximal  exercise,  heart  rate  and V˙O2 max were
ot  modiﬁed  by  nicotine;  however,  at  submaximal  levels,
hese  variables  and  cardiac  output  were  higher  [32]. Increas-
ngly  higher  heart  rates  and  blood  pressure  were  observed
ith  increasing  levels  of  exercise  intensity  [48];  however,
hether  such  an  effect  is  cumulative  with  the  intense  sym-
athetic  stimulation  due  to  physical  exertion  is  difﬁcult
o  establish  [24].  In  swine,  higher  plasma  catecholamine
evels  are  associated  with  nicotine  infusion  during  exer-
ise  [49];  this  elevation  was  less  pronounced  than  that
bserved  at  rest.  A  lower  response  to  stimulus  when  cat-
cholamine  levels  are  high,  as  in  exercise  conditions,  could
xplain  this  effect.  Stroke  volume  is  reduced  at  submaxi-
al  exercise  [32].  In  anaesthetized  swine,  rate  ×  pressure
roduct  (reﬂecting  myocardial  oxygen  consumption)  and
ystemic  resistances  during  exercise  were  raised  after  nico-
ine  absorption  [49];  however  these  modiﬁcations  were
ower  when  nicotine  was  infused  during  exercise  than  at
est.  Myocardial  blood  ﬂow  was  increased  to  a  lesser  extent
han  expected  from  studies  with  high  levels  of  myocar-
ial  work  [49].  Nicotine  was  found  to  limit  the  increase  in
yocardial  blood  ﬂow  during  heart  pacing  in  healthy  non-mokers  [46];  this  suggests  that  coronary  vasoconstriction
y  nicotine,  which  could  be  relevant  in  the  situation  of
 high  heart  rate  encountered  during  exercise  or  recov-
ry.  Because  endothelial  dysfunction  can  be  induced  by
e
T
Dicotine,  paradoxical  coronary  vasoconstriction  can  occur
uring  exercise  [7]. Splanchnic  vasoconstriction  and  the  sub-
equent  decrease  in  blood  ﬂow  induced  by  exercise  could
lso  impair  hepatic  nicotine  clearance  and  therefore  prolong
he  effects  of  nicotine  [32].
Heart  rate  at  recovery  remains  elevated  after  nicotine
ntake  [33,48].  Acetylcholine  induces  coronary  vasoconstric-
ion  in  the  presence  of  endothelial  dysfunction  [36].  This
an  occur  during  recovery,  with  a  vagal  hypertonic  state
fter  the  end  of  exercise.  Moreover,  nicotine  can  elicit  a
irect  coronary  vasoconstrictive  response  [47]. This  is  of
mportance,  as  the  effects  of  nicotine  may  be  enhanced  and
rolonged  by  exercise  [32].  The  signiﬁcant  effects  of  SLT
aken  before  a  sports  session  could  therefore  occur  after
xercise,  more  precisely  during  the  recovery  period.  Never-
heless,  whether  or  not  parasympathetic  stimulation  has  an
dditive  effect  on  vascular  tone  remains  to  be  determined.
ong-term effects
ong-term  cardiovascular  risk  associated  with  SLT  remains  a
atter  of  debate.  SLT  is  a  gateway  to  cigarette  smoking  and,
ike  cigarette  smoking,  can  induce  addiction  [3].  Moreover,
s  SLT  use  begins  at  an  early  age  [10,12,15]  (often  before  the
ge  of  15  years),  it  may  promote  premature  atherogenesis,
articularly  through  endothelial  dysfunction  [50].
an smokeless tobacco be considered as a
oping agent?
any  effects  of  nicotine  are  deleterious  during  exercise.
aemodynamic  modiﬁcations  can  compromise  myocardial
nd  muscular  vascularization,  muscular  strength  can  be
mpaired  and  anaerobic  threshold  is  reached  earlier.  How-
ver,  athletes  often  think  SLT  improves  their  performance.
his  obviously  raises  the  debate  about  doping.
To  be  included  in  the  forbidden  list  of  the  World  Anti-
oping  Agency  (WADA),  a  substance  or  method  must  fulﬁl  at
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dotted arrows: in case of endothelial dysfunction.
least  two  of  the  following  criteria:  enhances  performance;
induces  health  risk;  and  does  not  respect  the  spirit  of  sport
[51].
First,  nicotine  can  improve  some  aspects  of  performance,
by  enhancing  concentration  and  reactivity,  facilitating
movement  precision  and  reducing  anxiety;  such  proper-
ties  can  be  useful  in  many  sports.  The  weight-reducing
effect  is  relevant  in  sports  where  there  are  weight  cat-
egories.  Improvement  of  pain  tolerance  can  be  beneﬁcial
in  some  sports,  such  as  ﬁghting  sports.  Moreover,  delay-
ing  perception  of  fatigue  could  be  of  value  in  endurance
sports.
Second,  SLT  has  deleterious  effects  on  health  and  is
dangerous  for  the  cardiovascular  system  during  or  after
exercise.
Third,  as  SLT  use  can  be  addictive  and  considered  as  a
gateway  to  cigarette  smoking,  it  does  not  respect  the  spirit
of  sport.
Therefore,  as  SLT  fulﬁls  the  three  WADA  criteria,  SLT  may
be  considered  as  a  doping  agent.
Conclusion
Current  data  in  the  literature  strongly  suggest  that  SLT  has
deleterious  effects  on  human  health,  including  the  car-
diovascular  system.  SLT  is  used  extensively  in  the  sports
community  worldwide  and,  more  precisely,  in  snow  sports  in
Europe.  Nicotine  use  is  reported  in  the  monitoring  program
Ral exercise. Red: nicotine effects; blue: physical exercise effects;
nd  is  under  current  consideration  by  the  WADA.  Nicotine
se,  including  SLT,  fulﬁls  all  the  WADA  criteria  [51]  for  inclu-
ion  in  the  WADA  prohibited  list  as  a  doping  product.  Hence,
hewing  and  spit  tobacco,  as  well  as  dry  and  moist  snuff,
ust  therefore  be  discouraged,  particularly  when  sports
ctivities  are  considered.
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